NEOGEN CORP

NEOGNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$870.4M

▼ 2.7% YoY

Net Income

-$7.9M

▲ 99.3% YoY

EPS

$-0.04

▲ 99.2% YoY

Cash

$185.5M

▲ 43.8% YoY

FY 2026 · As of 2026-05-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.